Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers (HART-HN)

NCT05120947 NA COMPLETED Results posted

The primary purpose of this study is to determine the safe reduction of the treatment fractions to 10, 8, or 5, that may be delivered safely in resected head and neck squamous cell carcinoma (HNSCC) patients with intermediate pathologic risk features.

Details

Lead sponsor	Medical College of Wisconsin
Phase	NA
Status	COMPLETED
Enrolment	18
Start date	Wed Dec 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Nov 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Resectable Head and Neck Squamous Cell Carcinoma

Interventions

• 42 Gy Radiation Therapy
• 39 Gy Radiation Therapy
• 32.5 Gy Radiation Therapy

Countries

United States